文献速递膀胱癌与上尿路尿路上皮癌泌尿系感染

非肌层浸润性膀胱癌患者辅助膀胱内卡介苗灌注后卡介苗感染的累积发生率及危险因素

Cumulative incidence of and risk factors for BCG infection after adjuvant BCG instillations.
PubMed 文献 · BJU Int · 2024-02-25

基于瑞典全国数据库BladderBaSe 2.0,分析5033例接受辅助膀胱内卡介苗灌注的非肌层浸润性膀胱癌患者,卡介苗感染5年累积发生率为1.1%,感染发生率在开始灌注后前2年最高。女性风险低于男性(风险比0.23,95%置信区间0.07-0.74),其余因素未显示与风险相关。

要点

  • 辅助膀胱内卡介苗灌注后卡介苗感染5年累积发生率为1.1%(5033例)。
  • 感染发生率在开始灌注后前2年最高,需警惕此期间卡介苗感染的多样症状。
  • 女性风险低于男性(风险比0.23,95%置信区间0.07-0.74),但统计精度低且存在选择偏倚风险。

核心结论

  • 数据进一步支持非肌层浸润性膀胱癌卡介苗灌注治疗后卡介苗感染总体风险低。
  • 绝大多数感染发生在开始灌注后前2年,需在此期间警惕卡介苗感染的多样症状。
  • 研究提供男性为危险因素的证据,但统计精度低且存在选择偏倚风险,需不同方法的进一步研究才能排除其他推测的危险因素。

研究设计与样本

  • 基于瑞典全国数据库BladderBaSe 2.0分析卡介苗感染的发生时机、绝对与相对风险及其与患者特征的关系。
  • 卡介苗感染的累积发生率比例以患者登记中报告结核病诊断或开具抗结核药物处方来判定。
  • 共纳入5033例接受辅助膀胱内卡介苗灌注的患者。

主要发现

  • 5年随访时卡介苗感染的累积发生率比例为1.1%(5033例接受辅助膀胱内卡介苗灌注的患者)。
  • 感染发生率在开始卡介苗灌注后前2年最高。
  • 女性风险低于男性(风险比0.23,95%置信区间0.07-0.74)。
  • 诊断时年龄和日历时间、合并症、肿瘤风险组、既往使用皮质类固醇或免疫抑制药物、经尿道膀胱肿瘤电切术至开始辅助卡介苗灌注的时间均与风险无关。

局限性

  • 原文指出男性为危险因素的证据统计精度低。
  • 原文指出存在选择偏倚风险。
  • 原文指出需不同方法的进一步研究才能排除其他推测的危险因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the cumulative incidence proportion of disseminated or local Bacillus Calmette-Guérin (BCG) infections after adjuvant BCG instillations in patients with non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: We analysed the timing and occurrence of BCG infections and absolute and relative risk in relation to patient characteristics available in the Swedish nationwide database 'BladderBaSe 2.0'. The cumulative incidence proportion of a BCG infection was indicated by a reported diagnosis of tuberculosis (TB) in the patient registry or filing a prescription for tuberculostatic drugs. RESULTS: The cumulative incidence proportion was 1.1% at the 5-year follow-up in 5033 patients exposed to adjuvant BCG instillations. The incidence rate was highest during the first 2 years after start of BCG instillations. Women had a lower risk than men (hazard ratio 0.23, 95% confidence interval 0.07-0.74). Age and calendar time at diagnosis, comorbidity, tumour risk group, previous medication with corticosteroids, immunosuppressive drugs, or time between transurethral resection of the bladder tumour and commencing the adjuvant BCG instillation were not associated with risk. CONCLUSIONS: These data further supports that the overall risk of a BCG infection after BCG-instillation treatment for NMIBC is low. The great majority of infections occur in the first 2 years, calling for an awareness of the diverse symptoms of BCG infection during this period. We provide evidence for male sex as a risk factor; however, the statistical precision is low and with a risk of selection bias, making it difficult to rule out the other suggested risk factors without further studies with different approaches.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Holmberg L, Skogmar S, Garmo H, et al. Cumulative incidence of and risk factors for BCG infection after adjuvant BCG instillations. BJU Int. 2024. PMID: 38403809. doi:10.1111/bju.16303

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。